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Abstract Essentially, all cells release extracellular vesicles 
(EVs) that end up in biofluids, including blood, and the 
contents of these EVs can provide a window into the 
status of the cells from which they are released. This is 
particularly interesting in cancer, since these EVs allow 
for ‘ex-vivo’ analysis of the properties of the tumours 
without the need for biopsy. Gene mutations, 
rearrangements, amplifications, and epigenetic changes 
in the transcriptome can be monitored in circulating EVs. 
In this study, we used two human tumour cell lines 
derived from an epidermoid carcinoma and a 
medulloblastoma, which had amplification for the 
epidermal growth factor receptor (EGFR) and c-Myc 
genes, respectively. Cells were implanted subcutaneously 
into immunocompromised mice, and levels of gene  
 
amplification in both groups of subcutaneous tumours 
were quantified. We then determined if elevated levels of 
transcripts for the human EGFR and c-Myc were 
represented in circulating EVs in tumour-bearing mice. 
The expression levels of both human EGFR (h-EGFR) and 
human c-Myc (h-c-Myc) mRNAs in circulating EVs 
correlated well with their amplified status in the tumours. 
This data provides further support to the idea that 
circulating EVs are a potential platform for tumour 
biomarkers. 
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1. Introduction 
 
Brain tumours comprise a variety of phenotypic and 
genotypic subtypes. Currently, genetic analysis is 
performed on biopsies obtained during surgical tumour 
resection or by surgical biopsy at a later date for 
suspected recurrences. As many newly developed drugs 
target specific pathways affected by the genetic status of 
the tumour [1], understanding specific transcriptome 
signatures that characterize them is critical for 
personalized clinical care.  
 
Extracellular vesicles are nano-sized membrane bound 
particles released by essentially all cell types, including 
tumour cells, in vivo as well as in vitro, and comprise a 
mixed population of exosomes, shed microvesicles, and 
apoptotic blebs [2,3,4], collectively termed extracellular 
vesicles (EVs). They are found in all body fluids, 
including serum, plasma, cerebrospinal fluid (CSF), urine, 
and saliva [3], and can provide a window into the 
genotype and consequent phenotype of the tumour from 
which they are derived. The nucleic acid content of EVs 
provides a promising platform for companion diagnostics 
for monitoring tumour responses and changes during 
treatment [5, 6]. 
 
In the case of glioblastomas (GBMs), mutant oncogenic 
EGFRvIII mRNA and protein have been successfully 
detected in brain tumour-derived EVs found in the blood 
of GBM patients [6,7,8]. In addition, tumours are very 
dynamic entities and tend to change their genetic profile 
over time, especially after drug treatment and during 
recurrence. For example, lung cancer patients treated 
with EGFR tyrosine kinase inhibitors can relapse with a 
tumour harbouring a resistance mutation in EGFR [9]. 
This and other findings stress the importance of 
longitudinal tumour profiling to select and modify 
proper clinical treatment. Amplification of the epidermal 
growth factor receptor (EGFR) gene is a common event in 
GBMs and in about 40% of cases these amplified genomic 
fragments appear as double minute chromosomes [10]. 
Medulloblastoma is the most common and most 
malignant tumour of the central nervous system in 
children [11]. One histopathological feature that 
correlates with poor prognosis is large cell/anaplastic 
changes (20-25% of cases), which has been reported to be 
associated with amplifications in the c-Myc gene, with 
these amplifications being highly heterogeneous in the 
tumour tissue [11]. An EV-based assay for gene 
amplification would analyse nucleic acid derived from all 
cells in the tumour, thus having a better chance of 
representing different heterogeneous tumour 
characteristics. 
 
In this study, the RNA content of circulating EVs released 
by human tumours in xenograft mouse models was 
examined. The following two cell lines were used: brain 
tumour medulloblastoma cell line amplified for c-Myc, 
but not EGFR [6], and a peripheral tumour epidermoid 
carcinoma cell line amplified for EGFR, but not c-Myc 
[12]. Tumour cells were injected subcutaneously into both 
flanks of immunocompromised mice and tumours 
allowed to grow for one month. RNA was extracted from 
serum-derived EVs, as well as from the subcutaneous 
(s.c.) tumour tissues. Genomic DNA (gDNA) was also 
extracted from the s.c. tumours. Levels of human EGFR,
c-Myc and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNAs and gDNA were assessed by qRT-PCR 
and qPCR, respectively. Amplification of EGFR and c-
Myc were found to be well reflected in the corresponding 
mRNA extracted from circulating EVs in mice bearing 
epidermoid carcinomas and medulloblastoma tumours, 
respectively. This data supports the idea that serum EVs 
can provide an important platform for cancer biomarkers, 
in this case tumour gene amplification, and can provide 
useful information to tailor treatment strategies. 
 
2. Materials and Methods 
 
2.1 Cell lines 
 
Epidermoid carcinoma cell line A431 was obtained from 
ATCC and cultured in Dulbecco’s modified essential 
medium (DMEM; Invitrogen, Carlsbad, CA USA) 
containing 10% foetal bovine serum (FBS; JRH 
Biosciences, Lenexa, KS) and penicillin/streptomycin (10 
IU/ml and 10 μg/ml, respectively; Cellgro, Manassas, VA 
USA). Medulloblastoma cell lines D384 were obtained 
from Dr. Scott Pomeroy at Children’s Hospital, Boston, 
MA and were originally generated at Duke University. 
Medulloblastoma cell lines were cultured in suspension 
in DMEM containing 10% FBS, 1×GlutaMAX (Invitrogen) 
and penicillin/streptomycin (as above).  
 
2.2 Xenograft tumour models 
 
A431 cells were cultured as monolayers, and on the day 
of injection they were rinsed in PBS twice, resuspended 
using trypsin, and then diluted in FBS-free DMEM and 
centrifuged at 300 x g for 5 min to pellet the cells. D384 
cells were grown in suspension, and after being dispersed 
they were centrifuged for 5 min at 300 x g. The cell pellets 
(5.0 x 107 cells of each cell line) were resuspended in 500 
μl of PBS and mixed with 500 μl Matrigel (BD 
Biosciences, San Jose, CA USA). Five million cells per 
flank were injected into each flank of all animals (total of 
1.0 x 107 cells/mouse). Two groups of five adult mice 
(nu/nu, NCI) were each injected s.c. in both flanks with 
100 μl/5 x 106 epidermoid carcinoma (A431; five mice) or 
medulloblastoma (D384; five mice) cells per injection. 
Tumours were allowed to grow for a maximum of one 
month. Blood was drawn by cardiac puncture while mice 
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were under deep anaesthesia prior to sacrifice. 
Approximately 1 ml blood was collected into Eppendorf 
tubes and allowed to clot at room temperature for 1 hr. 
Samples were then centrifuged at 1,300 x g for 10 min. 
Approximately 600 μl serum from 1 ml of blood was 
separated, filtered through a 0.8 μm filter and stored at -
80C until further processing. Tumours were also 
resected, weighed and snap frozen in liquid nitrogen. All 
animal procedures were performed according to the 
guidelines issued by the Committee of Animal Care of 
Massachusetts General Hospital. 
 
2.3 Isolation of EVs and RNA extraction from serum  
and tumours 
 
Serum samples were thawed on ice and centrifuged at 
100,000 x g for 90 min using an Optima Max-XP, fixed 
angle MLA-55 rotor (k factor = 116; Beckman Coulter, 
Miami, FL, USA). The EVs pellets were lysed in Qiazol 
lysis buffer and RNA was extracted using the miRNeasy 
kit (Qiagen, Valencia, CA USA) according to the 
manufacturers’ recommendations. Tumour tissue was 
homogenized and RNA was extracted using the 
miRNeasy kit (Qiagen). Then, 50 ng of RNA from tumour 
tissue or EVs was used for qRT-PCR. RNA yield and 
purity was assessed using NanoDrop 2000 (Thermo 
Scientific, Wilmington, DE USA). 
 
2.4 Genomic DNA extraction 
 
Around 20 μg of tumour tissue was cut from the frozen 
samples of each animal (epidermoid carcinomas and 
medulloblastomas) and lysed overnight at room 
temperature using the Blood and Tissue DNA extraction 
kit (Qiagen, Valencia CA) as suggested by the 
manufacturer’s recommendations. The DNA was RNase 
treated using RNase A (Fermentas Inc., Glen Burnie, MD 
USA; 50 mg/ml) and the quality was assessed by 
NanoDrop 2000. Then, 10 ng of genomic DNA was used 
as input for each qPCR reaction.  
 
2.5 Reverse transcription and qPCR 
 
Twelve μL of the RNA from tumour tissue or EVs were 
reverse transcribed into cDNA using SuperScript® VILO™ 
cDNA Synthesis Kit (Invitrogen), according to the 
manufacturer’s recommendations. Samples were then 
preamplified using the TaqMan® PreAmp Master Mix 
(Applied Biosystems, Carlsbad, CA, USA). Briefly, 12.5μL of 
the cDNA was added to the PreAmp Master Mix together 
with human EGFR, c-Myc, and GAPDH primers and pre- 
amplified for 14 cycles, according to the manufacturer’s 
recommendations. Primers for the preamplification step are 
the same as those used in the TaqMan PCR (see below). The 
samples were then diluted 1:10 and TaqMan qRT-PCR was 
performed on all samples for the corresponding cDNA. The 
amplification was performed using ABI PRISM 7500 with 
the following program: 50°C, 2 min; 95°C, 10 min; 40 cycles 
of 95°C, 15 s; 60°C, 1 min on standard mode. Primers and 
probes were as follows: EGFR Forward: 
TATGTCCTCATTGCCCTCAACA; EGFR Reverse: 
CTGATGATCTGCAGGTTTTCCA; Fam labelled probe 
AAGGAATTCGCTCCACTG; c-Myc Forward 
CAACCCTTGCCGCATCCAC ; c-Myc Reverse 
AGTCGCGTCCTTGCTCGG; Fam labelled probe: 
AGCAGCGGGCGGGCACTTTGCACT; GAPDH Applied 
Biosystems kit, catalogue number Hs03929097_g1. All 
assays were specific for the human genes and did not 
detect any mouse sequences. 
 
2.6 Nanoparticle tracking analysis (NTA) 
 
Serum samples were diluted 1:3000 in PBS and particles 
were counted using the NanoSight LM-10 system 
(NanoSight, Amesbury, UK) supplemented with a fast 
video capture and nanoparticle tracking analysis (NTA) 
software. Particles were recorded for 30 secs per run and 
analysed using the following settings: gain set at 10; 
detection threshold set between three and seven 
depending on sample concentration. Each sample was 
measured three times and the data expressed as mean ± 
standard deviation. 
 
2.7 Statistics  
 
Statistical analyses were performed using the Student’s t-
test (two tailed). A value of p < 0.05 was considered 
significant. All data is represented as mean ± standard 
deviation (SD). 
3. Results  
 
3.1 Primary tumour gene amplification is reflected  
in circulating EVs 
 
Human epidermoid carcinoma (A431) and medulloblastoma 
(D384) tumour cells were injected subcutaneously into 
nude mice, and animals were monitored for one month. 
At the time of sacrifice, the mice were deeply 
anaesthetized and blood was collected by cardiac 
puncture, tumours were resected, and EVs were isolated 
from serum by high-speed ultracentrifugation for RNA 
qRT-PCR analysis. All data is normalized to GAPDH and 
represented as fold change compared to the tumour with 
the lowest levels of the gene of interest (i.e., non-
amplified for that gene and has the lowest level within 
the group); A431 tumours are represented as fold change 
compared to the D384 tumour with the lowest levels of 
human EGFR (h-EGFR); and D384 tumours are 
represented as fold change compared to the A431 tumour 
with the lowest levels of human c-Myc (h-c-Myc). Human 
EGFR mRNA in tumour tissues from epidermoid 
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carcinoma (A431) xenografts was elevated between 1.2 x 
105 and 3.5 x 105-fold compared to the medulloblastoma 
tumour D384 (not amplified for EGFR), while genomic 
DNA (gDNA) for h-EGFR was between 22 to 29-fold 
higher (Table 1). As expected, medulloblastoma xenograft 
tumour tissues (D384) had lower levels of h-EGFR mRNA 
in the range of 1.0-24-fold, with no elevation in h-EGFR 
gDNA levels (Table 1).  
 
EVs isolated from the serum of mice injected with the 
epidermoid carcinoma cell line had elevated levels of h-
EGFR mRNA in the range of 46—1.3 x 106-fold, while 
RNA from serum-EVs of medulloblastoma (D384) 
tumours had on average lower amounts of h-EGFR 
mRNA, ranging from 1.0-73-fold (Figure 1 and Table 1). 
Three animals injected with the medulloblastoma cell line 
(D384) had high levels of circulating h-EGFR RNA (31-73-
fold), although the tumour tissue itself did not show any 
h-EGFR amplification, suggesting an increase in 
transcription rather than amplification (Table 1). On 
average there was about 100,000 times more h-EGFR 
mRNA in epidermoid carcinomas tumour tissue when 
compared to medulloblastoma tumour tissue (p≤0.001). 
The difference in h-EGFR mRNA levels in EVs from mice 
with epidermoid carcinoma tumours, as compared to 
medulloblastoma tumours, was also highly significant 
(p≤0.001; Figure 1A). EVs from the epidermoid carcinoma 
tumour in mouse A431–1 had the lowest levels of 
circulating h-EGFR RNA, which was more comparable to 





Figure 1. EGFR and c-Myc amplifications in the primary tumour are reflected in circulating EVs. Human EGFR and c-Myc mRNA levels 
were quantified in circulating EVs from xenograft models injected with either an epidermoid carcinoma cell line (A431; n=5) or a 
medulloblastoma cell line (D384; n=5), respectively. Box plot graph represents levels of h-EGFR (A) and h-c-Myc (B) mRNA in Ct values 
(lower Ct corresponds to higher levels of the message). The data is normalized to h-GAPDH mRNA levels. Values are represented as 
average ± S.D. (h-EGFR p≤0.001, as compared to D384 which is not amplified for EGFR; n=5 per group; n.d. = not detected). 
 
 Tumour Tissue Circulating EVs 
  h-c-Myc  h-EGFR h-c-Myc h-EGFR 
  gDNA ±S.D. 
mRNA




fold ±S.D. mRNA fold ±S.D. 
A431 - 1 1.0 ±0.8 2.2 ±0.1  28 ±1.1 257,905 ±17,203 n.d. n.d. 46 ±0.4 
A431 - 2 0.9 ±0.1 1.0 ±0.1 22 ±1.3 122,516 ±4,069 n.d. n.d. 1,042 ±148  
A431 - 3 1.0 ±0.2 2.5 ±0.6  26 ±1.4 219,609 ±9,660 n.d. n.d. 1,230 ±89  
A431 - 4 1.1 ±0.1 3.7 ±0.1 24 ±1.0 354,072 ±4,831 n.d. n.d. 908 ±26  
A431 - 5 0.8 ±0.1 3.9 ±0.1 29 ±1.3 154,010 ±6,906 n.d.  n.d. 1,327,610 ±64,262  
                          
D384 - 1 20 ±1.2 45 ±2.9  1.2 ±0.1 1.1 ±0.1 2,910 ±356  73 ±2.4 
D384 - 2 21 ±1.3 30 ±0.6  1.2 ±0.1 24 ±0.3 1.962 ±36  67 ±0.4  
D384 - 3 20 ±1.1 39 ±3.9  1.1 ±0.2 1.4 ±0.1 976 ±30  31 ±0.7 
D384 – 4 19 ±1.3 27 ±1.1  1.0 ±0.1 17 ±0.2 126 ±14 1.0 ±0.1 
D384 - 5 22 ±1.1 51 ±4.0  1.2 ±0.2 1.0 ±0.2 1.5 ±0.6 2.1 ±0.1  
Table 1. Human c-Myc and EGFR mRNA fold change normalized to GAPDH in xenograft tumour tissue and circulating EVs as well as 
level of genomic DNA (gDNA) 
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Figure 2. Particle counts and tumour sizes in mouse xenografts. 
Five animals were used in each group and injected in both flanks 
with either epidermoid carcinomas (A; A431) or 
medulloblastoma (B; D384) tumour cells. After one month 
tumours were resected, masses recorded and snap frozen in 
liquid nitrogen; serum was collected and stored at -80°C for gene 
amplification analysis. For NanoSight analysis, serum was 
diluted 1:3000 and particles were counted. Particle counts are 
represented as mean ± S.D. The Y-axis represents EVs counts and 
the X-axis represents tumour masses. 
 
Human c-Myc mRNA in tumour tissues from 
medulloblastoma tumours (D384) was elevated between 
27-51-fold compared to the c-Myc non-amplified 
epidermoid tumour (A431—1 set to 1), while gDNA for 
h-c-Myc was 19-22-fold higher (Table 1). The levels of 
circulating h-c-Myc at EVs reflected this amplification, 
ranging from a 1.5-2.910-fold increase as compared to the 
c-Myc non-amplified epidermoid carcinoma group (A431 
set to Ct = 37/non-detectable). Human c-Myc RNA was 
not detected in EVs from any of the epidermoid 
carcinoma xenografts (Figure 1B and Table 1). 
 
3.2 Xenograft tumour sizes and circulating EV (particle) counts 
 
Medulloblastoma (D384) and epidermoid carcinoma 
(A431) tumours were resected after one month of in vivo 
growth. Tumours were weighed and recorded as follows: 
A431-1 – 1.14g, A431-2 – 0.96g, A431-3 – 1.06g, A431-4 – 
1.06g, A431-5 – 0.6g, D384-1 – 1.01g, D384-2 – 0.43g, D384-3 
– 0.54g, D384-4 – 0.54g, D384-5 – 1.65g. Epidermoid 
carcinoma (A431) and medulloblastoma (D384) tumour 
masses were on average 0.9 ± 0.2g (Figure 2A) and 0.8 ± 
0.5g (Figure 2B), respectively. Serum samples from 
xenografts were diluted 1:3000 with PBS and counted 
using nanoparticle tracking analysis (NTA). Pearson 
correlation between particle number and tumour size 
revealed there to be no correlation in epidermoid 
carcinoma tumours (A431; r2=0.2). Medulloblastoma 
tumours (D384) showed an initial correlation (4/5 mice) but 
the largest tumour had a low number of circulating EVs, 




Tumour-derived EVs provide a promising platform for 
cancer biomarkers. They provide a window into the 
genetic status of the tumour by allowing ‘sampling’ of the 
tumour from a distant, accessible site. Once released from 
tumour cells, EVs can end up in the bloodstream where 
they can be isolated and analysed for tumour markers 
and expression signatures. One of the major challenges of 
this field is the high background of EVs released from 
normal cells that contain a ‘wild-type’ transcriptome. 
Several approaches have been used to enrich for tumour-
specific EVs and the field is currently expanding to 
include new and more advanced techniques, such as 
microfluidics [13], magnetic resonance imaging signals 
[8], antibody specific capturing [13], and streptavidin 
beads [14]. Currently, a widely used technique for EV 
isolation is ultracentrifugation, which sediments particles 
based on their size so that both normal and tumour cell-
derived EVs are collected, although variations in recovery 
vary with fluid viscosities [15]. We have previously 
reported that human c-Myc RNA is found in circulating 
EVs from xenograft models injected with a 
medulloblastoma cell line [6]. In this study, we show that 
levels of gene amplification of c-Myc and EGFR in human 
tumour lines are reflected in circulating EVs. Xenograft 
mouse models were used and were injected with human 
cancer cell lines amplified for a specific oncogene, either 
EGFR (A431) or c-Myc (D384). Mice were then sacrificed 
and tumours removed and serum collected for RNA 
analysis of EVs. EVs were isolated by filtration and 
differential centrifugation, and RNA was analysed for 
quantity of human EGFR, c-Myc and GAPDH mRNAs. 
 
Epidermoid carcinoma EGFR amplification was well-
represented in circulating EVs from A431 mouse models. 
Overall, Ct values for h-EGFR mRNA in circulating EVs 
from mice bearing epidermoid carcinomas (A431) 
amplified at the genomic level for this oncogene were 
lower (corresponding to higher amounts; p≤0.001), than 
h-EGFR levels from medulloblastoma (D384)-derived EVs 
not amplified for this oncogene (Figure 1A). Human 
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EGFR gene amplification levels in the primary tumours 
were in concordance with what has been previously 
reported for cultured A431 cells [16]. Human EGFR 
mRNA levels in circulating EVs varied greatly among 
different tumour-bearing mice with one of them having 
1.6 x 106-fold more EGFR message (compared to GAPDH 
message). This mouse did not have the highest levels of 
EGFR mRNA in the primary tumour or the highest 
number of circulating EVs (Figure 2A). In fact, this mouse 
had the smallest tumour size (0.6 g) in that group, but it 
appeared to be the most malignant tumour, as the mouse 
was cachexic (data not shown). This difference in the 
levels of EGFR mRNA in the primary tumour and 
circulating EVs may be due to increased transcription 
rates of mRNA and the subsequent more aggressive 
behaviour of the tumour. In addition, different copies of 
mRNA could exist at different locations, stabilities, and 
translations, and thus this kind of variation might be 
expected. High vascularization and invasion of the 
tumour may be another reason for such high malignancy, 
which in turn results in a lower body mass. Furthermore, 
only a small portion of circulating EVs are thought to be 
of tumour origin (5-10%), and this may indicate that these 
EVs exerted their immune-suppressive properties on the 
host immune cells, thus decreasing the total number of 
circulating normal EVs. This inhibition may have led to 
enrichment of the tumour-derived EVs and thus explains 
the high levels of h-EGFR mRNA in EVs detected by 
qPCR. Another epidermoid carcinoma in one mouse 
(A431-1) had very low levels of h-EGFR mRNA in 
circulating EVs (Table 1). The size of the tumour was 
similar to those in A431-2, A431-3 and A431-4 mice, but 
the number of vesicles was around 70% less compared to 
these three animals, which may account for the lower 
level of h-EGFR mRNA in circulating EVs (Figure 2).  
 
Human c-Myc mRNA was detected in circulating EVs from 
all five xenografts injected with the medulloblastoma cell 
line (D384) and was not detected in circulating EVs isolated 
from mice injected with the epidermoid carcinoma (A431) 
cell line. Worth noting is that human c-Myc mRNA was not 
as high in the medulloblastoma tumour as EGFR mRNA 
was in the epidermoid carcinoma tumour (average mRNA 
increase was 29 vs. 1.1 x 105, respectively). The data 
suggests that, most likely, at least an 18-fold amplification 
for h-c-Myc in the tumour is required for detection in 
circulating EVs, while h-EGFR can be detected even when 
not amplified (data normalized to GAPDH and expressed 
as fold difference compared to h-EGFR non-amplified 
tumour [17]). One reason for this could be the difference in 
the half-life for these mRNA species, which is relatively 
short for c-Myc and therefore may be degraded before 
packaging inside EVs [18], or different localization of h-c-
Myc and h-EGFR mRNAs inside the cells. According to 
the proposed kinetic model of RNA, genes encoding 
mRNAs with short half-lives are more likely to respond 
quickly to transcriptional activation or suppression [19]. 
Thus, the intrinsic stability of the mRNA would be 
expected to affect the rate of induction as well as the 
suppression of mRNA levels, because transcripts with 
short half-lives can respond more rapidly than stable 
transcripts to changes in transcription rates. The 
difference in h-c-Myc and h-EGFR RNA detection in EVs 
may also suggest specific packaging mechanisms for 
human EGFR mRNA into EVs, possibly exacerbated by 
the fact that this is occurring in a mouse background—
especially because in 4/5 mice, h-c-Myc mRNA levels in 
EVs were higher than in the tumour itself. There seems to 
be a slight increase in EV numbers as tumour size 
increases, but this is not reflected in all animals. This may 
be due to the small sample size as well as the malignant 
nature of the tumour; in fact, epidermoid carcinomas 
(A431) cannot grow very large because the mouse quickly 
becomes heavily sick (data not shown), which may not 
allow enough time to detect an increase in circulating 
EVs. Medulloblastoma tumours, on the other hand, 
showed an initial increase in circulating EV number, but 
the animal with the largest tumour had a low circulating 
EVs count (Figure 2B), suggesting a higher malignancy, 
which may have inhibited the number of normal host-
derived circulating EVs. Another variability might be the 
degree of vascularization of the tumour, which could lead 
to a different number of circulating EVs.  
 
Within the limitations of an animal study, this study 
confirms the notion that EVs provide a potential platform 
for tumour biomarkers. Genetic mutations, 
rearrangements, and amplifications are reflected in RNA 
in EVs released by the tumour cells [20]. These EVs can be 
isolated from biofluids and provide a window into 
studying the primary tumour, either at diagnosis or later 
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